We are so close to reaching our goal! It's not to late to JOIN or DONATE to MOVE to BEAT CANCER and help those across Canada diagnosed with kidney cancer! We need your help! Every donation matters! JOIN or DONATE to an existing team or member NOW! movetobeatcancer.org

Join us for our September patient & caregiver Coffee Chat on September 30th @ 3 PM EST. Grab a favourite drink cozy up & join our warm, welcoming kidney cancer community. Whether you're newly diagnosed, a long-time survivor or caregiver, you’re invited! Join on our website!

C'est le moment idéal pour vous installer confortablement, prendre votre boisson d'automne préférée et rejoindre notre communauté chaleureuse et accueillante de personnes touchées par le cancer du rein pour le Coffee Talk de ce mois-ci. Septembre 30th 7pm cancerdurein.ca

Friendly Friday Reminder! It's NOT TO LATE to DONATE to MOVE to BEAT CANCER! We are so close to reaching our goal t o help provide care to Canadians diagnosed with kidney cancer! Every donation matters and creates a difference! DONATE NOW! movetobeatcancer.org

I live in a mountain town - sometimes in the winter telehealth is the ONLY way I can see my oncologist. Please call your elected representatives and demand they preserve telehealth coverage!

The CUA26 logo by @inchipakwetrust blends Saskatoon's skyline with 6 Saskatoon berries—honoring Treaty 6 land. A symbol of gathering, knowledge-sharing, and connection, it reflects the spirit and purpose of #CUA26. #LetsGoSaskatooning

🎂Happy Birthday Marfisa! Thanks for all you do. Hope you celebrated your special day. 💚 Kidney Cancer Canada Cancer du rein CA

Board member Margie Hickey led the IKCC quarterly Connect and Share webinar, with participants joining from four continents. The topic discussed was how to work with the pharmaceutical industry. (1/2)

She covered many important topics, such as networking, funding, budget cycles, general guidelines, and regulations. Thank you, Margie, for sharing your valuable experience. (2/2)

We’re calling on the #KidneyCancer research community: help shape #KCRS26! Submit your session proposal and bring new science, fresh perspectives, and impactful ideas to next year’s summit. We’re seeking sessions that connect preclinical, translational, and clinical research

Community Connections on October 16th!!! Join us in person or catch the livestream on YouTube.com/ellicsrkitchen, 12 to 1pm ET

The CUASF Vision is to ensure a sustainable thriving urological research community in Canada, you can apply for these grants on >>> cuasf.org

Americas too busy curing cancer to troll X 😁

On stage sharing our work in geriatric and palliative care, with my 6-year-old daughter and Paulo G Bergerot in the audience cheering me on. Nothing like family support to make the moment even more special! 💖🎤 ASCO #ASCOQLTY25

We are truly grateful for your membership, and the vital work you do each and every day.🍂🍁 Nous vous sommes profondément reconnaissants, pour votre collaboration et le travail essentiel que vous accomplissez chaque jour.

@kidneycancercanada would like to share with our patient & caregiver community this webinar presented by the Canadian Cancer Survivor Network! Reducing Scan-xiety! October 15 2025 Register through the link below 💚 survivornet.ca/learn/ccsn-web…

Join Laurence Albiges Sumanta K. Pal, MD, FASCO Marc-Oliver Grimm and I as we discuss #kidneycancer treatment updates and pearls at the Ipsen Symposium Saturday at 630pm ESMO - Eur. Oncology #ESMO25. Looking forward to great discussion! OncoAlert IKCC Kidney Cancer Canadian Urological Association KidneyCAN Kidney Cancer

Doctors! Tell us YOUR answer! How should the term “cure” be used in #kidneycancer? #ESMO25 Let’s see how many responses we can get! Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Yüksel Ürün Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Uromigos OncoAlert surveymonkey.com/r/MDCure

The RAMPART is thankfully positive making it the second adjuvant immunotherapy trial in #kidneycancer along with KN564 with Pembrolizumab. Driven by high risk group. Included non clear cell but should look at that subgroup more. Awaiting OS. #ESMO25 OncoAlert

Proud of Andy Hahn for presenting LENCABO. OS appears similar but there is a PFS difference. There are toxicity differences so patient selection is important as usual. #ESMO25 @oncoalert